Press Release September 14, 2022

ACELYRIN Completes $300 Million Series C

The Technology and Life Sciences teams advised ACELYRIN in the completion of its $300 million Series C financing round which was led by Access Biotechnology with participation from ACELYRIN's existing investors AyurMaya – an affiliated fund of Matrix Capital Management, Westlake Village BioPartners, Cowen Healthcare Investments, Decheng Capital, Marshall Wace, OrbiMed, Samsara BioCapital, Surveyor Capital (a Citadel company), Tybourne Capital Management, and venBio Partners.

ACELYRIN will use the financing to fund its izokibep Phase 3 development in psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA) through anticipated submission of biologic license applications (BLA). Combined with significant cash on hand, the company will also continue development of izokibep in hidradenitis suppurativa (HS) and uveitis, explore several potential new indications, and continue to aggressively pursue portfolio expansion through high-value business development opportunities.

ACELYRIN is a Los Angeles area-based biopharma company – with additional operations in the San Francisco Bay area – focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates and leveraging its expertise to rapidly advance these medicines to patients.

The Goodwin team was led by Jon Novotny, Steven Green, Patrick Sims, Shane Albright, Marianne Sarrazin, Jacob Osborn, Alexander Varond, Maggie Wong, Gozde Guckaya and Emilee Wu.

For additional details on the financing round, please read the press release and coverage in the Wall Street Journal and Endpoints News.